Placental alkaline phosphatase to control diabetes

DETAILED DESCRIPTION In one embodiment, the present invention provides a method of reducing plasma glucose level in a mammal, comprising the step of administering a therapeutically effective amount of purified human placental alkaline phosphatase, or an active derivative.
The mammal may be a human.
The method may be effective to reduce a human's blood glucose level to below about 10 mM, and preferably into the normal range of 4 mM to 7 mM.
The method may be used on a diabetic human, and may be used in combination with administration of an anti-diabetic medicament.
In another embodiment, the invention provides a treatment regimen for treating diabetes, comprising periodically administering to a diabetic human a therapeutically effective amount of purified human placental alkaline phosphatase, or an active derivative.
The treatment regimen may be used in combination with administration of an anti-diabetic medicament.
The treatment regimen may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM.
In another embodiment, the invention provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.